Please Wait...

  • +91 22 2783 1455

  • Product background
    LAVINA CEFTRIAXONE FOR INJECION (Ceftriaxone for Injection USP 1 g)

WARNING: CAUTION : PLEASE NOTE :
The content or product detailing is not intended to replace advice from your prescribing doctor or healthcare professional. Lavina Pharma is not responsible for such actions by consumers. For any further information about the product please contact +91 22 2783 1455 and we can provide you the details.

Ceftriaxone is indicated in the treatment of the following infections in adults and children including term neonates (from birth):

·      Bacterial Meningitis

·      Community acquired pneumonia

·      Acute otitis media

·      Intra-abdominal infections

·      Urinary tract infections

·      Infections of joint and bones

·      Skin and soft tissue infections

·      Gonorrhoea, Syphilis

·      Bacterial endocarditis

·      For treatment of acute exacerbations of chronic obstructive pulmonary disease in adults

·      For treatment of disseminated Lyme borreliosis (early (stage II) and late (stage III)) in

adults and children including neonates from 15 days of age.

·      Pre-operative prophylaxis of surgical site infections

Ceftriaxone is a broad-spectrum third-generation cephalosporin antibiotic used to treat a variety of bacterial infections in adults and children, including newborns. It is effective against conditions such as bacterial meningitis, pneumonia, urinary tract infections, skin and soft tissue infections, and sexually transmitted diseases like gonorrhoea and syphilis. It is also used in treating bone and joint infections, intra-abdominal infections, and for preventing infections during surgery. Ceftriaxone is commonly administered via injection and is known for its convenient once-daily dosing.


COMPOSITION

Each vial contains:

Sterile Ceftriaxone Sodium USP

Eq. to Ceftriaxone anhydrous ………….. 1g 

Intramuscular administration/ Intravenous administration 

DOSAGE

As directed by the physician.

SIDE EFFECT

•    Pain, Induration, Tenderness at the site of infection (1%) less frequently phlebitis was seen       

     after IV doses.

•    Rash, Pruritus, Fever, Chills

•    Eosinophilia, Thrombocytosis, Leukopenia, Anaemeia, Neutropenia, Lymphopenia,

     Thrombocytopenia

•    Diarrhoea, Nausea, vomiting, Diageusia

•    Headache, dizziness

•    Moniliasis/vaginitis





PRECAUTION

In renal failure no adjustment may be necessary but serum level should be monitored periodically and the dosage reduced if required. Dosage adjustment is similarly not essential in hepatic failure but in patients with hepatic and significant renal malfunction. Lavincef doses should not exceed 2 g/day without close serum monitoring. Rarely, alterations in prothrombin time have occurred and may require coadministration of vitamin K (10 mg weekly). Prolonged use may cause overgrowth of non-susceptible organism and cause hyper infection. Administer with caution to patients with history of G.I. diseases, especially, colitis.




PRESENTATION

50 glass vials of 10 ml packed in a carton along with pack insert